TrialDiabetes care2014

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Michael Nauck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.